Meanwhile, since inhibitors of PLAGL2 downstream effectors EGFR and C‐MET showed only modest effects in advanced‐stage HCC or phase 2 trials,32 the discovery of efficient PLAGL2 inhibitors is urgently needed for HCC targeted therapy. The gene discussed is PLAGL2; the disease is hepatocellular carcinoma.